The current outbreak of Ebola has devastated communities in West Africa. It has also thrown a light on the complex web of IP rights surrounding the possible treatments for this serious and usually fatal virus, as LSIPR discovered.
Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS.
A recent decision from the IPAB on the patent eligibility of biological processes could change the biotech playing field in India, say Swarup Kumar and Shivaarti Bajaj.
The Bay Area of California has one of the greatest concentrations of life sciences companies in the world, but its biotech community is being threatened by the seemingly unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler, vice chair, of the new North Bay Life Science Alliance to find out how it plans to strengthen the network in the area.
Increasing numbers of patent challengers are finding the USPTO’s post-grant procedures to be attractive alternatives to district court litigation, write Arlene Chow and Peter Noh.
For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch.
The EPO generally accepts applications relating to human embryonic stem cells with an effective date after 2008 but discussions about eligibility continue, says Joachim Wachenfeld.
Digital health, which brings together digital and genetic data to improve healthcare, will play a vital role in personalised medicine. But there will be significant challenges when it comes to protecting this innovative new area. LSIPR looks at its uses and the potential challenges.
The USPTO’s new guidance for examiners extends the decision in Myriad beyond isolated nucleic acids to all claims concerning ‘judicial exceptions’. Bethan Hopewell and Jennifer Antcliff report.
For those involved in the development of biological drugs, the prospects of getting what would seem to be a ‘fair reward’ may not have improved much, says Jaap Mannaerts.